According to incomplete statistics from Innovation Radar, last week (June 23 to June 29), the global pharmaceuticals and healthcare sectorA total of 23 financing events were disclosed, with a total financing amount exceeding 390 million US dollars.。

Small Molecule New Drug R&D CompanyTransThera Listed on the Hong Kong Stock ExchangeCurrently, the company has six clinical-stage candidate products, among which,Tinengotinib is a multi-target kinase (MTK) inhibitor., mainly targeting three key pathways: FGFR/VEGFR, JAK, and Aurora kinase, for the treatment of cholangiocarcinoma (CCA) patients who are resistant to FGFR inhibitors. The company is also exploring its application in various solid tumors such as metastatic castration-resistant prostate cancer, breast cancer, and biliary tract cancers, and plans to evaluate the efficacy of combination immunotherapy for hepatocellular carcinoma.

In the field of neurological diseases,Neuron23 Completes $96.5 Million Series D Financing, will advance the global Phase 2 clinical trial of NEU-411, a brain-penetrant, highly selective LRRK2 inhibitor for the treatment of early-stage Parkinson's disease (PD) patients.

In the field of cell therapy,Huawei Hengyuan Completes Tens of Millions of Yuan in Series A1 Financing, focusing on innovation in the treatment of immunometabolic diseases and assisted reproduction. The company has established clinical-gradeInduced Pluripotent Stem Cells (iPSC) and editing transformation platform, as well as a universal transplantation protection vector platform. It is reported that the rheumatoid arthritis cell injection developed by the company will enter the clinical trial stage; the diabetes immune-exemption artificial pancreas project is in the preclinical research and IND application preparation stage.

In addition, there are examples such asTingSheng Technology, ChengGe Bio, JieShi Medical, Archimedes VascularMultiple companies, including ..., have received financing.

Readers, please star⭐Chuangjianhui to receive updates第一时间收到推送.

Disclaimer: This article is for the purpose of information exchange only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it mean WuXi AppTec supports or opposes the views mentioned in the article. This article is not a recommendation of any treatment plan. For guidance on obtaining a treatment plan, please visit a regular hospital.

Copyright Statement: Welcome to share to Moments. Unauthorized media or institutions are prohibited from reprinting or copying in any form to other platforms. For reprint authorization, please contact"Chuangjian Hui"Contact us through the WeChat Official Account message.

More Data Content Recommended

Click "InSee", Sharing the Latest Health Trends from Chuangjian Hui